

Marina de Bernard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2438088/publications.pdf>

Version: 2024-02-01

82
papers

5,088
citations

76326

40
h-index

88630

70
g-index

84
all docs

84
docs citations

84
times ranked

5021
citing authors

#	ARTICLE	IF	CITATIONS
1	Triggering of Inflammasome by Aggregated α -Synuclein, an Inflammatory Response in Synucleinopathies. PLoS ONE, 2013, 8, e55375.	2.5	465
2	The neutrophil-activating protein of <i>Helicobacter pylori</i> promotes Th1 immune responses. Journal of Clinical Investigation, 2006, 116, 1092-1101.	8.2	280
3	Cellular vacuoles induced by <i>Helicobacter pylori</i> originate from late endosomal compartments.. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, 9720-9724.	7.1	232
4	Inhibition of Intracellular Cholesterol Transport Alters Presenilin Localization and Amyloid Precursor Protein Processing in Neuronal Cells. Journal of Neuroscience, 2002, 22, 1679-1689.	3.6	232
5	The small GTP binding protein rab7 is essential for cellular vacuolation induced by <i>Helicobacter pylori</i> cytotoxin. EMBO Journal, 1997, 16, 15-24.	7.8	203
6	Low pH Activates the Vacuolating Toxin of <i>Helicobacter pylori</i> , Which Becomes Acid and Pepsin Resistant. Journal of Biological Chemistry, 1995, 270, 23937-23940.	3.4	197
7	The m2 form of the <i>Helicobacter pylori</i> cytotoxin has cell type-specific vacuolating activity. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 10212-10217.	7.1	184
8	<i>Helicobacter pylori</i> Vacuolating Toxin Forms Anion-Selective Channels in Planar Lipid Bilayers: Possible Implications for the Mechanism of Cellular Vacuolation. Biophysical Journal, 1999, 76, 1401-1409.	0.5	145
9	Bafilomycin A1 inhibits <i>Helicobacter pylori</i> -induced vacuolization of HeLa cells. Molecular Microbiology, 1993, 7, 323-327.	2.5	134
10	<i>Helicobacter pylori</i> toxin VacA induces vacuole formation by acting in the cell cytosol. Molecular Microbiology, 1997, 26, 665-674.	2.5	128
11	<i>Helicobacter pylori</i> secreted peptidyl prolyl cis, trans-isomerase drives Th17 inflammation in gastric adenocarcinoma. Internal and Emergency Medicine, 2014, 9, 303-309.	2.0	118
12	Identification of the <i>Helicobacter pylori</i> VacA Toxin Domain Active in the Cell Cytosol. Infection and Immunity, 1998, 66, 6014-6016.	2.2	102
13	Autoimmune gastritis: histology phenotype and OLGA staging. Alimentary Pharmacology and Therapeutics, 2012, 35, 1460-1466.	3.7	101
14	The neutrophil-activating protein of <i>Helicobacter pylori</i> down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cellular Microbiology, 2008, 10, 2355-2363.	2.1	100
15	MicroRNA expression profiling in human Barrett's carcinogenesis. International Journal of Cancer, 2011, 129, 1661-1670.	5.1	100
16	Molecular and cellular mechanisms of action of the vacuolating cytotoxin (VacA) and neutrophil-activating protein (HP-NAP) virulence factors of <i>Helicobacter pylori</i> . Microbes and Infection, 2003, 5, 715-721.	1.9	97
17	<i>Borrelia burgdorferi</i> NapA-driven Th17 cell inflammation in lyme arthritis. Arthritis and Rheumatism, 2008, 58, 3609-3617.	6.7	93
18	The neutrophil-activating protein of <i>Helicobacter pylori</i> (HP-NAP) as an immune modulating agent. FEMS Immunology and Medical Microbiology, 2007, 50, 157-164.	2.7	88

#	ARTICLE	IF	CITATIONS
19	The Neutrophil-Activating Protein of <i>Helicobacter pylori</i> Crosses Endothelia to Promote Neutrophil Adhesion In Vivo. <i>Journal of Immunology</i> , 2007, 178, 1312-1320.	0.8	87
20	The Acid Activation of <i>Helicobacter pylori</i> Toxin VacA: Structural and Membrane Binding Studies. <i>Biochemical and Biophysical Research Communications</i> , 1998, 248, 334-340.	2.1	84
21	Endosome-mitochondria juxtaposition during apoptosis induced by <i>H. pylori</i> VacA. <i>Cell Death and Differentiation</i> , 2010, 17, 1707-1716.	11.2	80
22	3D imaging of the 58 kda cell binding subunit of the <i>Helicobacter pylori</i> cytotoxin. <i>Journal of Molecular Biology</i> , 1999, 290, 459-470.	4.2	77
23	The neutrophil-activating protein (HP-NAP) of <i>Helicobacter pylori</i> is a potent stimulant of mast cells. <i>European Journal of Immunology</i> , 2002, 32, 671.	2.9	76
24	A pH-sensitive stearyl-PEG-poly(methacryloyl sulfadimethoxine)-decorated liposome system for protein delivery: An application for bladder cancer treatment. <i>Journal of Controlled Release</i> , 2016, 238, 31-42.	9.9	75
25	Cytokine BAFF Released by <i>Helicobacter pylori</i> -Infected Macrophages Triggers the Th17 Response in Human Chronic Gastritis. <i>Journal of Immunology</i> , 2014, 193, 5584-5594.	0.8	62
26	Oxidative DNA damage in gastric cancer: CagA status and OGG1 gene polymorphism. <i>International Journal of Cancer</i> , 2008, 123, 51-55.	5.1	61
27	The immune modulating activity of the <i>Helicobacter pylori</i> HP-NAP: Friend or foe?. <i>Toxicon</i> , 2010, 56, 1186-1192.	1.6	60
28	Tumor-associated macrophages as major source of APRIL in gastric MALT lymphoma. <i>Blood</i> , 2011, 117, 6612-6616.	1.4	55
29	<i>Helicobacter pylori</i> , asthma and allergy. <i>FEMS Immunology and Medical Microbiology</i> , 2009, 56, 1-8.	2.7	53
30	<i>Chlamydomonas reinhardtii</i> phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 1222-1227.	7.1	53
31	Molecular and cellular activities of <i>Helicobacter pylori</i> pathogenic factors. <i>FEBS Letters</i> , 1999, 452, 16-21.	2.8	50
32	Immunosuppression of TH2 responses in <i>Trichinella spiralis</i> infection by <i>Helicobacter pylori</i> neutrophil-activating protein. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 122, 908-913.e5.	2.9	46
33	HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 31-40.	4.2	46
34	Simulating Inflammation in a Wound Microenvironment Using a Dermal Wound-on-a-Chip Model. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801307.	7.6	46
35	<i>Helicobacter pylori</i> Affects the Antigen Presentation Activity of Macrophages Modulating the Expression of the Immune Receptor CD300E through miR-4270. <i>Frontiers in Immunology</i> , 2017, 8, 1288.	4.8	45
36	Virulence factors of <i>Helicobacter pylori</i> . <i>International Journal of Medical Microbiology</i> , 2001, 290, 647-658.	3.6	44

#	ARTICLE	IF	CITATIONS
37	TpF1 from <i>Treponema pallidum</i> Activates Inflammasome and Promotes the Development of Regulatory T Cells. <i>Journal of Immunology</i> , 2011, 187, 1377-1384.	0.8	44
38	The concerted action of the <i>Helicobacter pylori</i> cytotoxin VacA and of the v-ATPase proton pump induces swelling of isolated endosomes. <i>Cellular Microbiology</i> , 2007, 9, 1481-1490.	2.1	42
39	The effect of <i>Helicobacter pylori</i> on asthma and allergy. <i>Journal of Asthma and Allergy</i> , 2010, 3, 139.	3.4	42
40	Pathogenesis of <i>Helicobacter pylori</i> Infection. <i>Helicobacter</i> , 2014, 19, 11-18.	3.5	42
41	The <i>Helicobacter pylori</i> VacA cytotoxin activates RBL-2H3 cells by inducing cytosolic calcium oscillations. <i>Cellular Microbiology</i> , 2005, 7, 191-198.	2.1	41
42	The <i>Vibrio cholerae</i> haemolysin anion channel is required for cell vacuolation and death. <i>Cellular Microbiology</i> , 2002, 4, 397-409.	2.1	39
43	The neutrophil-activating protein (HP-NAP) of <i>Helicobacter pylori</i> is a potent stimulant of mast cells. <i>European Journal of Immunology</i> , 2002, 32, 671-676.	2.9	34
44	A <i>Helicobacter pylori</i> Vacuolating Toxin Mutant That Fails To Oligomerize Has a Dominant Negative Phenotype. <i>Infection and Immunity</i> , 2006, 74, 1786-1794.	2.2	34
45	Immunosuppressive and Proinflammatory Activities of the VacA Toxin of <i>Helicobacter pylori</i> . <i>Journal of Experimental Medicine</i> , 2003, 198, 1767-1771.	8.5	33
46	The <i>Vibrio cholerae</i> Cytolysin Promotes Chloride Secretion from Intact Human Intestinal Mucosa. <i>PLoS ONE</i> , 2009, 4, e5074.	2.5	32
47	Orchestration of Inflammation and Adaptive Immunity in <i>Borrelia burgdorferi</i> -Induced Arthritis by Neutrophil-Activating Protein A. <i>Arthritis and Rheumatism</i> , 2013, 65, 1232-1242.	6.7	32
48	Cell vacuolization induced by <i>Helicobacter pylori</i> VacA toxin: cell line sensitivity and quantitative estimation. <i>Toxicology Letters</i> , 1998, 99, 109-115.	0.8	31
49	The multiple cellular activities of the VacA cytotoxin of <i>Helicobacter pylori</i> . <i>International Journal of Medical Microbiology</i> , 2004, 293, 589-597.	3.6	31
50	Bacterial toxins with intracellular protease activity. <i>Clinica Chimica Acta</i> , 2000, 291, 189-199.	1.1	30
51	Cell vacuolization induced by <i>Helicobacter pylori</i> : Inhibition by bafilomycins A1, B1, C1 and D. <i>FEMS Microbiology Letters</i> , 1993, 113, 155-159.	1.8	28
52	Cell vacuolization induced by <i>Helicobacter pylori</i> VacA cytotoxin does not depend on late endosomal SNAREs+. <i>Cellular Microbiology</i> , 2002, 4, 11-18.	2.1	28
53	Supercritical carbon dioxide combined with high power ultrasound as innovative drying process for chicken breast. <i>Journal of Supercritical Fluids</i> , 2019, 147, 24-32.	3.2	28
54	<i>Treponema pallidum</i> (syphilis) antigen TpF1 induces angiogenesis through the activation of the IL-8 pathway. <i>Scientific Reports</i> , 2016, 6, 18785.	3.3	27

#	ARTICLE	IF	CITATIONS
55	The lipoprotein <i>HP1454</i> of <i>Helicobacter pylori</i> regulates T cell response by shaping T cell receptor signalling. <i>Cellular Microbiology</i> , 2019, 21, e13006.	2.1	27
56	Let-7c down-regulation in <i>Helicobacter pylori</i> -related gastric carcinogenesis. <i>Oncotarget</i> , 2016, 7, 4915-4924.	1.8	26
57	IFN- γ and R-848 Dependent Activation of Human Monocyte-Derived Dendritic Cells by <i>Neisseria meningitidis</i> Adhesin A. <i>Journal of Immunology</i> , 2007, 179, 3904-3916.	0.8	25
58	vOX2 glycoprotein of human herpesvirus 8 modulates human primary macrophages activity. <i>Journal of Cellular Physiology</i> , 2009, 219, 698-706.	4.1	25
59	Glibenclamide Stimulates Fluid Secretion in Rodent Cholangiocytes Through a Cystic Fibrosis Transmembrane Conductance Regulator-Independent Mechanism. <i>Gastroenterology</i> , 2005, 129, 220-233.	1.3	24
60	VacA and HP-NAP, Ying and Yang of <i>Helicobacter pylori</i> -associated gastric inflammation. <i>Clinica Chimica Acta</i> , 2007, 381, 32-38.	1.1	24
61	The <i>Helicobacter cinaedi</i> antigen CAIP participates in atherosclerotic inflammation by promoting the differentiation of macrophages in foam cells. <i>Scientific Reports</i> , 2017, 7, 40515.	3.3	24
62	<i>Helicobacter pylori</i> Dampens HLA-II Expression on Macrophages via the Up-Regulation of miRNAs Targeting CIITA. <i>Frontiers in Immunology</i> , 2019, 10, 2923.	4.8	22
63	The C2 fragment from <i>Neisseria meningitidis</i> antigen NHBA increases endothelial permeability by destabilizing adherens junctions. <i>Cellular Microbiology</i> , 2014, 16, 925-937.	2.1	21
64	<i>Helicobacter pylori</i> antigenic Lpp20 is a structural homologue of Tip1 and promotes epithelial-mesenchymal transition. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 3263-3271.	2.4	19
65	<i>Helicobacter pylori</i> -derived neutrophil-activating protein increases the lifespan of monocytes and neutrophils. <i>Cellular Microbiology</i> , 2010, 12, 754-764.	2.1	18
66	The immune receptor CD300e negatively regulates T cell activation by impairing the STAT1-dependent antigen presentation. <i>Scientific Reports</i> , 2020, 10, 16501.	3.3	16
67	TPA and butyrate increase cell sensitivity to the vacuolating toxin of <i>Helicobacter pylori</i> . <i>FEBS Letters</i> , 1998, 436, 218-222.	2.8	12
68	Structure and immunomodulatory property relationship in NapA of <i>Borrelia burgdorferi</i> . <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2010, 1804, 2191-2197.	2.3	12
69	To treat or not to treat <i>Helicobacter pylori</i> to benefit asthma patients. <i>Expert Review of Respiratory Medicine</i> , 2010, 4, 147-150.	2.5	11
70	HP-NAP of <i>Helicobacter pylori</i> : The Power of the Immunomodulation. <i>Frontiers in Immunology</i> , 0, 13, .	4.8	11
71	The <i>Vibrio cholerae</i> cytotoxin promotes activation of mast cell (T helper 2) cytokine production. <i>Cellular Microbiology</i> , 2008, 10, 899-907.	2.1	8
72	<i>Helicobacter Pylori</i> HP0175 Promotes the Production of IL-23, IL-6, IL-1 β and TGF- β . <i>European Journal of Inflammation</i> , 2013, 11, 261-268.	0.5	7

#	ARTICLE	IF	CITATIONS
73	ADP-ribose enables <i>Helicobacter pylori</i> to exploit macrophages as a survival niche by suppressing antigen-presenting HLA expression. <i>FEBS Letters</i> , 2021, 595, 2160-2168.	2.8	7
74	Macrophage-Mediated Melanoma Reduction after HP-NAP Treatment in a Zebrafish Xenograft Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1644.	4.1	7
75	Tumor Cells and the Extracellular Matrix Dictate the Pro-Tumoral Profile of Macrophages in CRC. <i>Cancers</i> , 2021, 13, 5199.	3.7	6
76	Toll-like receptors hit calcium. <i>EMBO Reports</i> , 2014, 15, 468-469.	4.5	5
77	Cerebrospinal Fluid T-Regulatory Cells Recognize <i>Borrelia burgdorferi</i> Napa in Chronic Lyme Borreliosis. <i>International Journal of Immunopathology and Pharmacology</i> , 2013, 26, 907-915.	2.1	4
78	Evaluation of the Efficacy of the <i>H. pylori</i> Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model. <i>Journal of Visualized Experiments</i> , 2015, , e52743.	0.3	4
79	Reply to letter by Nardelli and Schell commenting on the pathogenesis of lyme arthritis. <i>Arthritis and Rheumatism</i> , 2009, 60, 2205-2205.	6.7	3
80	Cell vacuolization induced by <i>Helicobacter pylori</i> : Inhibition by bafilomycins A1, B1, C1 and D. <i>FEMS Microbiology Letters</i> , 1993, 113, 155-159.	1.8	1
81	HP-NAP new therapy for bladder cancer: numquam periculum sine periculo vincitur. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 447-448.	4.2	0
82	BAFFling Autoimmune Disorders and <i>Helicobacter pylori</i> Disease: The Interplay between BAFF and the Th17 Response. <i>Clinical Immunology, Endocrine and Metabolic Drugs</i> , 2015, 2, 4-5.	0.3	0